AURO-ESLICARBAZEPINE 200 MG — DIN 02527421
ESLICARBAZEPINE ACETATE : 200 MG · AURO PHARMA INC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is AURO-ESLICARBAZEPINE?
AURO-ESLICARBAZEPINE 200 MG contains ESLICARBAZEPINE ACETATE : 200 MG. It is listed in the Health Canada Drug Product Database under DIN 02527421, held by AURO PHARMA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 08-May-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is AURO-ESLICARBAZEPINE used for?
Auro-Eslicarbazepine (eslicarbazepine acetate) is indicated as: • Monotherapy in the management of partial-onset seizures in adult patients with epilepsy. All patients who participated in the monotherapy trial were newly or recently diagnosed with epilepsy (see CLINICAL TRIALS ). • Adjunctive therapy in the management of adults, and children above 6 years of age, with partial-onset seizures who are not satisfactorily controlled with conventional therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Eslicarbazepine cost around the world?
Eslicarbazepine is listed on 2 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Hungary publishes a producer price (ex-factory); United States publishes a acquisition. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 4 | 28 | USD███.██ |
| Hungary | producer price (ex-factory) | 1 | 1 | HUF███.██ |
29 pack listings across 5 brand entries and 2 price bases, refreshed 03 Sep 2026. Ranges span every Eslicarbazepine pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Eslicarbazepine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
3 holders have a Canadian DIN containing Eslicarbazepine, across 12 DINs, of which 8 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| APOTEX INC | 4 | 4 | APO-ESLICARBAZEPINE | Sourceable in Canada |
| AURO PHARMA INC | 4 | 4 | AURO-ESLICARBAZEPINE | Sourceable in Canada |
| SUMITOMO PHARMA CANADA, INC. | 4 | 0 | APTIOM | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 200 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | null |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Eslicarbazepine |
|---|---|
| ATC code | N03AF04 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02527421 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2527421 |
| Brand name | AURO-ESLICARBAZEPINE |
| Generic / active ingredient | ESLICARBAZEPINE ACETATE : 200 MG |
| Market authorization holder | AURO PHARMA INC |
| Health Canada schedule | Prescription |
| ATC code | N03AF04 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N03AF |
| Current status | MARKETED |
| Status date | 08-May-2025 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
8 of 12 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-ESLICARBAZEPINE | 800 MG | TABLET | APOTEX INC | MARKETED | 02537974 |
| APO-ESLICARBAZEPINE | 200 MG | TABLET | APOTEX INC | MARKETED | 02537931 |
| APO-ESLICARBAZEPINE | 600 MG | TABLET | APOTEX INC | MARKETED | 02537966 |
| APO-ESLICARBAZEPINE | 400 MG | TABLET | APOTEX INC | MARKETED | 02537958 |
| AURO-ESLICARBAZEPINE | 600 MG | TABLET | AURO PHARMA INC | MARKETED | 02527456 |
| AURO-ESLICARBAZEPINE | 400 MG | TABLET | AURO PHARMA INC | MARKETED | 02527448 |
| AURO-ESLICARBAZEPINE | 800 MG | TABLET | AURO PHARMA INC | MARKETED | 02527464 |
| APTIOM | 200 MG | TABLET | SUMITOMO PHARMA CANADA, INC. | CANCELLED POST MARKET | 02426862 |
| APTIOM | 800 MG | TABLET | SUMITOMO PHARMA CANADA, INC. | CANCELLED POST MARKET | 02426897 |
| APTIOM | 600 MG | TABLET | SUMITOMO PHARMA CANADA, INC. | CANCELLED POST MARKET | 02426889 |
2 · Same class — other molecules in ATC N03AF
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Carbamazepine | APO-CARBAMAZEPINE · APO-CARBAMAZEPINE CR · BIO-CARBAMAZEPINE · CARBAMAZEPINE 200 TAB 200MG · +26 more | 46 | 11 | Yes |
| Oxcarbazepine | APO-OXCARBAZEPINE · JAMP OXCARBAZEPINE · JAMP-OXCARBAZEPINE · NOVO-OXCARBAZEPINE · +6 more | 22 | 9 | Yes |
| Eslicarbazepine | APO-ESLICARBAZEPINE · APTIOM · AURO-ESLICARBAZEPINE | 12 | 8 | Yes |
| Rufinamide | AURO-RUFINAMIDE · BANZEL | 6 | 5 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N03A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N03AX | Brivaracetam · Cannabidiol · Cenobamate · Lacosamide · Lamotrigine · +4 more | 391 | 197 |
| N03AG | Valproic Acid · Vigabatrin | 75 | 19 |
| N03AA | Phenobarbital · Primidone | 39 | 13 |
| N03AB | Fosphenytoin · Phenytoin · Phenytoin, Combinations | 17 | 8 |
| N03AE | Clonazepam | 55 | 8 |
| N03AD | Ethosuximide · Mesuximide | 5 | 4 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.